Alkermes Pharma Ireland Limited

Alkermes is an Irish biopharmaceutical company dedicated to developing innovative medicines that improve lives by addressing unmet medical needs in psychiatry and sleep disorders, headquartered in Ireland.

Here are key aspects of the company:

• Products & Services: The company develops investigational oral orexin 2 receptor agonists like alixorexton for narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia, as well as a once-nightly formulation of sodium oxybate extended-release oral suspension.
• Industries: Alkermes focuses its research and development efforts on psychiatry and sleep disorders, specifically targeting conditions such as schizophrenia, bipolar I disorder in pediatric populations, narcolepsy type 1, narcolepsy type 2, idiopathic hypersomnia, and narcolepsy.
• Innovation: The organization is currently evaluating multiple therapies in Phase 3 studies including REVITALYZ for sodium oxybate extended-release and the ENLIGHTEN-Youth study for olanzapine and samidorphan in pediatric patients with schizophrenia and bipolar I disorder.

Alkermes demonstrates a strong commitment to scientific advancement through its active participation in major clinical conferences and ongoing development of novel treatments for complex neurological conditions.